Reducing Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes: TeleECHO Series
Silvio E Inzucchi, MD
Director, Yale Medicine Diabetes Center
Professor of Medicine, Endocrinology
Yale University School of Medicine
New Haven, CT
Robert Busch, MD
Endocrinology, Diabetes & Metabolism
AMC Community Division
The Endocrine Group
Dhiren Patel, PharmD, CDE, BC-ADM, BCACP
Clinical Pharmacy Specialist – Endocrine
VA Boston Healthcare System
Adjunct Associate Professor of Pharmacy Practice
Anne L. Peters, MD
Professor of Medicine (Clinical Scholar)
Keck School of Medicine
University of Southern California
Westside Center for Diabetes Off Campus
Beverly Hills, CA
Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
Medical Director, AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Orlando, Translational Research Institute
This case-based enduring activity will cover the diagnosis, treatment, and management of patients with Atherosclerotic Cardiovascular Disease and Type 2 Diabetes.
This educational activity is intended for primary care physicians in the United States who treat adults with type 2 diabetes.
After completing the CME activity, learners should be better able to:
- Discuss current treatment recommendations for primary and secondary prevention of atherosclerotic cardiovascular disease in patients with type 2 diabetes
- Evaluate clinical trial data on the use of GLP-1 receptor agonists and SGLT2 inhibitors to reduce cardiovascular events in patient with type 2 diabetes
- Review updated treatment guidelines that incorporate patient-specific factors and evidence from recent cardiovascular outcome trials to improve glycemic control and reduce cardiovascular risk in patients with type 2 diabetes
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with type 2 diabetes mellitus.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Dr. Inzucchi discloses that he is consultant for Boehringer Ingelheim, AstraZeneca, Sanofi/Lexicon, Novo Nordisk, Merck, vTv Therapeutics, Zafgen, Abbott/Alere, Eisai (TIMI). He has also received royalties from McGraw-Hill and Uptodate and has received salary from Elsevier.
Dr. Busch discloses that he is on the speakers’ bureaus for Boehringer Ingelheim, Janssen, Lilly, and Novo Nordisk.
Dr. Patel discloses that he has received consulting fees from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Insulet, Merck, Novo Nordisk, and Sanofi. Dr. Patel is on the speakers’ bureaus for Amarin, Astra Zeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Merck, Novo Nordisk, Valeritas, and Xeris.
Dr. Peters discloses that she is on the speakers’ bureau for Novo Nordisk. She is a consultant for Abbott Diabetes Care, Becton Dickinson, Boehringer Ingelheim, Eli Lilly and Company, Lexicon, Livongo, MannKind, Medscape, Merck, Novo Nordisk, Omada Health, OptumHealth, sanofi, and Zafgen. Dr. Peters has also received research support from AstraZeneca, Dexcom, and MannKind.
Dr. Richard Pratley discloses that he is a speaker for Novo Nordisk, a consultant for GlaxoSmithKline, Janssen, Lilly, Merck, Novo Nordisk and Sanofi, and has received grants from Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Lilly, Merck, Novo Nordisk and Sanofi. All honoraria directed toward a non-profit which supports education and research.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Russie Allen, Outcomes Coordinator for Med Learning Group has nothing to disclose.
Nicole Longo, DO, FACOI, Medical Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Melissa A Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: May 13, 2020
EXPIRATION DATE: May 13, 2021
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at firstname.lastname@example.org
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.